January 17, 2017

Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017

Company CEO to Present on Friday, January 20th at 12:40 pm EST

NEW YORK and CLEVELAND, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, Ph.D., will present and participate in a panel discussion at the Phacilitate Cell & Gene Therapy World 2017 Conference in Miami, FL.

The following are the specific details regarding Abeona Therapeutics Presentation & Panel Discussion:

Presentation: Therapeutic Area Clinical Update: CNS - Case Study 4
Date: Friday, January 20th, 2017
Time: 12:40 pm EST
Location: Miami, FL
Website: http://www.bioleaders-forum.com/conferences

Panel: Translational Academy: Where it possible to do higher impact novel biotherapeutic research today – academia or industry?
Date: Thursday, January 19th, 2017
Panel Timing: 1:45 pm EST
Panelists Include:
Timothy J. Miller, PhD, President & CEO, Abeona Therapeutics Inc.
J. Joseph Melenhorst, PhD, Director of Product Development & Correlative Sciences, Center for Cellular Immunotherapies, University of Pennsylvania
Greg Bonfiglio, Founder & Managing Partner, Proteus, LLC
Olivier Danos, SVP, Biogen
Moderator: Dr Shashi Murthy, Professor, Northeastern University

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene

editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Investor Contact:
Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212
csilverstein@abeonatherapeutics.com

Media Contact:
Andre'a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com

Source: Abeona Therapeutics Inc